ISRCTN16320108已完成不适用
A randomised placebo controlled double blind clinical trial comparing selenium and pentoxifylline in patients with mild Graves' orbitopathy - EUGOGO study B
Academic Medical Centre (AMC) (The Netherlands)0 个研究点目标入组 156 人开始时间: 2006年2月14日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 156
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Graves' hyperthyroidism, euthyroid for at least two months by antithyroid drugs or surgery (at least 6 months if I131 is used)
- •2. Mild Graves' ophthalmopathy (at least 1 sign), with a disease duration of less than 18 months
- •3. No past treatment of the ophthalmopathy except for local measures
- •4. Aged 18 - 70 years
排除标准
- •1. NOSPECS class 2c
- •2. Proptosis greater than 22 mm
- •3. Diplopia in primary or reading position and/or ocular torticollis
- •4. Mono-ocular duction in any direction of less than 20 degrees
- •5. Optic nerve involvement
- •6. Pregnancy, drugs/alcohol abuse, severe concomitant illness, no informed consent, use of selenium or pentoxifylline containing preparations
研究者
相似试验
已完成
不适用
A randomised placebo controlled double blind clinical trial of vitamin D in the treatment of tuberculosisInfections and InfestationsTuberculosisISRCTN35212132Bandim Health Project (Guinea-Bissau)500
已完成
2 期
Complementary and Alternative Medicine and the menopausal transition: The effect of a Chinese Herbal Formula on Vasomotor symptoms and bone turnover.MenopauseACTRN12608000617369Global Therapeutics Pty Ltd90
已完成
2 期
Clinical and physiological evaluation of a Chinese herbal medicine for constipation-predominant Irritable Bowel Syndrome (C-IBS Trial).Constipation-predominant Irritable Bowel SyndromeAlternative and Complementary Medicine - Herbal remediesACTRN12609000558224niversity of Western Sydney160
尚未招募
3 期
A double blind randomised placebo controlled clinical trial for evaluating the efficacy of Eranda Patra Kshara and Hingu churna with lifestyle modification in the management of Non-alcoholic fatty liver diseaseCTRI/2023/04/052096All India Institute of Ayurveda
已完成
3 期
Rituximab in patients with primary Sjögren's syndromeISRCTN65360827niversity of Leeds (UK)110